Press Releases 2011


 
2014 | 2013 | 2012 | 2011
DateTitle 
December 20, 2011Incyte to Present at the 30th Annual J. P. Morgan Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 20, 2011-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 30th Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2012 at 8:30 a.m. (PT) / 11:30 a.m. (ET) in San Francisco. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors in... 
Printer Friendly Version
December 12, 2011First FDA-Approved Treatment for Myelofibrosis, Jakafi™ (ruxolitinib), Discussed in Multiple Presentations at 2011 ASH Annual Meeting
Incyte to host a webcast for investors featuring these results on Monday, December 12 at 7:00 p.m. PT SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2011-- Incyte Corporation (Nasdaq:INCY) today announced that further analyses from the global, pivotal Phase III clinical program of Jakafi (ruxolitinib or INC424) are being presented at the 2011 American Society of Hematology (ASH) Annual Meeting. The presentations include: Verstovsek S, et... 
Printer Friendly Version
November 30, 2011Incyte to Present at the Oppenheimer & Co. 22nd AnnualHealthcare Conference
WILMINGTON, Del., Nov 30, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the Oppenheimer & Co. 22nd Annual Healthcare Conference on Wednesday, December 14, 2011 at 3:20 p.m. (ET) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in listenin... 
Printer Friendly Version
November 18, 2011Incyte to Present at the 23rd Annual Piper Jaffray Health Care Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 18, 2011-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29, 2011 at 4:30 p.m. (ET) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 30 days. Investors interested in ... 
Printer Friendly Version
November 16, 2011FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis
- First and Only FDA-Approved Treatment For Potentially Life-Threatening Blood Cancer - Product Available Next Week; Incyte Establishes Comprehensive Patient Assistance Program - Conference Call Scheduled, Today at 12:30 PM ET WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 16, 2011-- Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi™ ... 
Printer Friendly Version
October 27, 2011Incyte Reports Third Quarter 2011 Financial Results and Provides Update on Key Clinical Programs
New Drug Application (NDA) for ruxolitinib as a treatment for myelofibrosis filed and granted priority review by the US Food and Drug Administration (FDA); PDUFA date set for December 3, 2011 Commercialization activities advance; sales force recruitment completed Amendment to the Special Protocol Assessment (SPA) for RESPONSE, the Phase III trial for patients with advanced polycythemia vera, a... 
Printer Friendly Version
October 13, 2011Incyte to Report Third Quarter 2011 Financial Results and Provide Update on Key Clinical Programs on October 27
WILMINGTON, Del., Oct 13, 2011 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2011 financial results conference call for 8:30 a.m. ET on Thursday, October 27, 2011. The schedules for the press release and conference call are as follows: -- Q3 2011 Press Release: October 27, 2011 at 7:00 a.m. ET -- Q3 2011 Conference Call: October 27, 2011 at 8:30 a.m. ET -- Domestic Dial In Number: 877-407-8037 -- Inter... 
Printer Friendly Version
August 30, 2011Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del., Aug 30, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of September: Robert W. Baird & Co. 2011 Health Care Conference on Thursday, September 8, 2011 at 1:45 p.m. (ET) in New York City; Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2011 at 11:30 a.m. (ET) in New York City; ... 
Printer Friendly Version
August 03, 2011FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis
Application Granted Priority Review PDUFA Date Set for December 3, 2011 WILMINGTON, Del., Aug 03, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Incyte's lead investigational compound, ruxolitinib (INCB18424/INC424), as a potential treatment for patients with myelofibrosis (MF). MF is a potentially life-thre... 
Printer Friendly Version
July 28, 2011Incyte Reports Second Quarter 2011 Financial Results and Provides Update on Key Clinical Programs
New Drug Application (NDA) for ruxolitinib as a treatment for myelofibrosis submitted to US Food & Drug Administration (FDA) Pivotal Phase III results for ruxolitinib demonstrating significant clinical benefit in patients with myelofibrosis presented at ASCO and EHA Commercialization activities ongoing; sales force recruitment initiated Conference Call Scheduled Today at 8:3... 
Printer Friendly Version
July 13, 2011Incyte Reports Second Quarter 2011 Financial Results andProvides Update on Key Clinical Programs on July 28
WILMINGTON, Del., Jul 13, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2011 financial results conference call for 8:30 a.m. ET on Thursday, July 28, 2011. The schedules for the press release and conference call are as follows: -- Q2 2011 Press Release: July 28, 2011 at 7:00 a.m. ET ... 
Printer Friendly Version
June 11, 2011Incyte Reports Additional Analyses of Symptomatic Improvement andQuality of Life with Ruxolitinib (INC424) in Patients with Myelofibrosis from the COMFORT-I Study
Results Presented at 16th Congress of the European Hematology Association LONDON, Jun 11, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK inhibitor Treatment), a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with ... 
Printer Friendly Version
June 06, 2011Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration
WILMINGTON, Del., Jun 06, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA). Incyte is seeking US marketing approval of ruxolitinib for the treatment of myelofibrosis (MF), a potentially life-threatening blood cancer for which there are currently no approved therapies in the US... 
Printer Friendly Version
June 04, 2011Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
A potentially life-threatening blood cancer with limited treatment options, myelofibrosis is characterized by bone marrow failure, enlarged spleen and highly debilitating symptoms Both Phase III studies, COMFORT-I conducted by Incyte and COMFORT-II conducted by Novartis, met their primary efficacy endpoint and provide the basis for US and EU filings in June Highlights from the ruxolitinib clinical program are being reported ... 
Printer Friendly Version
May 24, 2011Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del., May 24, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of June: Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 11:30 a.m. (ET) in New York City; Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 2:40 p.m. (PT) in California; and ... 
Printer Friendly Version
May 03, 2011Incyte Reports First Quarter 2011 Financial Results and Program Updates
Second Phase III Trial of Ruxolitinib, COMFORT-II, Conducted by Novartis, Achieved Primary Endpoint in First Quarter Ruxolitinib U.S. and E.U. Regulatory Submissions on Track for Second Quarter Data from COMFORT-I and COMFORT-II Accepted for Oral Presentations at ASCO and EHA Conference Call Scheduled Today at 8:30 a.m. ET WILMINGTON, Del., May 03, 2011 (BUSINESS WIRE) --Incy... 
Printer Friendly Version
April 27, 2011Incyte to Present at the Bank of America Merrill Lynch Healthcare Conference
WILMINGTON, Del., Apr 27, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10, 2011 at 4:20 p.m. (PT) / 7:20 p.m. (ET) in Las Vegas, NV. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 30 days. Investors interested in ... 
Printer Friendly Version
April 14, 2011Incyte to Report First Quarter 2011 Financial Results and Provide Update on Drug Discovery & Development Programs on May 3
WILMINGTON, Del., Apr 14, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2011 financial results conference call for 8:30 a.m. ET on Tuesday, May 3, 2011. The schedules for the press release and conference call are as follows: -- Q1 2011 Press Release: May 3, 2011 at 7:00 a.m. ET ... 
Printer Friendly Version
April 05, 2011Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology Program
WILMINGTON, Del., Apr 05, 2011 (BUSINESS WIRE) --Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $15 million payment from Novartis based on the achievement of a predefined milestone in an ongoing Phase I dose- escalation trial for INCB28060 (also known as INC280) in patients with solid tumors. This trial is being conducted by Incyte as part of its worldwide collaboration and license agreement with Novartis under which Incyte ... 
Printer Friendly Version
March 15, 2011Incyte's Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Data from Novartis COMFORT-II European Phase III trial show treatment with ruxolitinib provided a statistically significant reduction in spleen size in patients with myelofibrosis when compared with best available therapy Myelofibrosis is a debilitating disease with a poor prognosis and limited therapies, presenting a critical unmet medical need US New Drug Application submission by Incyte and EU Marketing Authorizatio... 
Printer Friendly Version
February 23, 2011Incyte to Present at the Cowen and Company 31st Annual Health Care Conference
WILMINGTON, Del., Feb 23, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the Cowen and Company 31st Annual Health Care Conference on Wednesday, March 9, 2011 at 9:30 a.m. (ET) in Boston. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 30 days. Investors interested in listening to the ... 
Printer Friendly Version
February 10, 2011Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives and Financial Guidance
--Positive clinical results and strong financial position advance Company towards commercialization -- Conference Call Scheduled Today at 8:30 a.m. ET WILMINGTON, Del., Feb 10, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) today reported fourth quarter and full year 2010 financial results, provided 2011 key objectives, and announced its 2011 financial guidance. "The advancements made in all of our clinical programs in 2010 were remarkable, espec... 
Printer Friendly Version
January 28, 2011Incyte to Report 2010 Financial Results and Provide 2011 Key Objectives and Financial Guidance on February 10
WILMINGTON, Del., Jan 28, 2011 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter/year-end 2010 financial results conference call for 8:30 a.m. ET on Thursday, February 10, 2011. The schedules for the press release and conference call are as follows: Q4 & YE 2010 Press Release: February 10, 2011 at 7:00 a.m. ET Q4 & YE 2010 Conference Call: February 10, 2011 at 8:30 a.m. ET Domestic Dial In Number: 877-407-8037 ... 
Printer Friendly Version
January 03, 2011Incyte to Present at the 29th Annual J.P. Morgan Healthcare Conference
WILMINGTON, Del., Jan 03, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 30 days. Investors interested in li... 
Printer Friendly Version